Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS long-term open-label bitopertin extension in EPP/XLP
2025-523275-27-00Phase 3Authorised
- Sponsor
- Disc Medicine
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Disc Medicine. Primary endpoint: Safety and tolerability of bitopertin. Planned start May 2026; status: authorised.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on 2025-523275-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523275-27-00.